Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES

Liver International

Volumn 36, Issue 9, 2016, Pages 1275-1283

  Butt, Adeel A ^a,b,c,d   Yan, Peng ^a   Shaikh, Obaid S ^a,e   Chung, Raymond T ^f,g   Sherman, Kenneth E ^h  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b HAMAD MEDICAL CORPORATION   (Qatar)

^c WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

adherence; directly acting antiviral agents; ERCHIVES; HCV; sofosbuvir

Indexed keywords

BOCEPREVIR; LEDIPASVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT; INTERFERON; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PROLINE;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; TREATMENT RESPONSE; VETERAN; AGED; ANALOGS AND DERIVATIVES; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; COMPLICATION; FACTUAL DATABASE; GENETICS; GENOTYPE; HEPACIVIRUS; MEDICATION COMPLIANCE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROLINE; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE; UNITED STATES; VETERANS;

EID: 84961744670     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13103     Document Type: Article

References (26)

1. Backus LI, Belperio PS, Shahoumian TA, Cheung R, Mole LA. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93–103.
2. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clin Infect Dis 2012; 54: 96–104.
3. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis 2013; 13: 401–8.
4. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100–7.
5. Hayashi N, Izumi N, Kumada H, et al. Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 14: 10.
6. Izumi N, Hayashi N, Kumada H, et al. Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941–53.
7. Delgado JS, Baumfeld Y, Novack V, et al., et al. Efficacy of combined pegylated interferon and ribavirin therapy in Jewish patients of Israel suffering from chronic hepatitis C. Hepatol Int 2011; 5: 985–90.
8. Chen TM, Huang PT, Wen CF, et al. Reappraisal of the importance of mutations in the NS5A-PKR-binding domain of hepatitis C-1b virus in the era of optimally individualized therapy. J Viral Hepat 2011; 18: 119–28.
9. Vo KP, Vutien P, Akiyama MJ, et al. Poor sustained virological response in a multicenter real-life cohort of chronic hepatitis C patients treated with pegylated interferon and ribavirin plus telaprevir or boceprevir. Dig Dis Sci 2015; 60: 1045–51.
10. Butt AA, Yan P, Shaikh OS, et al. Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings. J Viral Hepat 2015; 22: 691–700.
11. Gonzalez-Colominas E, Broquetas T, Retamero A, et al. Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. Liver Int 2015; 35: 1557–65.
12. Calvo-Cidoncha E, Gonzalez-Bueno J, Meida-Gonzalez CV, Morillo-Verdugo R. Influence of treatment complexity on adherence and incidence of blips in HIV/HCV coinfected patients. J Manag Care Spec Pharm 2015; 21: 153–7.
13. Roux P, Fugon L, Winnock M, et al. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users. Addiction 2012; 107: 152–9.
14. Hansen RA, Dusetzina SB, Dominik RC, Gaynes BN. Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010; 19: 33–37.
15. Hansen RA, Kim MM, Song L, et al. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother 2009; 43: 413–22.
16. Butt AA, Khan UA, McGinnis KA, Skanderson M, Kwoh CK. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Viral Hepatitis 2007; 14: 890–6.
17. Butt AA, Wang X, Budoff M, et al. Hepatitis C virus infection and the risk of coronary disease. Clin Infect Dis 2009; 49: 225–32.
18. Butt AA, Wang X, Moore CM. Effect of HCV and its treatment upon survival. Hepatology 2009; 50: 387–92.
19. Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver International 2009; 30: 240–50.
20. Butt AA, Wang X, Fried LF. HCV infection and the incidence of chronic kidney disease. Am J Kid Dis 2011; 57: 396–402.
21. Erqou S, Mohanty A, McGinnis KA, et al. Hepatitis C virus treatment and survival in patients with hepatitis C and human immunodeficiency virus co-infection and baseline anaemia. J Viral Hepat 2013; 20: 463–9.
22. Mohanty A, Erqou S, McGinnis KA, et al. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia. Clin Gastroenterol Hepatol 2013; 11: 741–7.
23. Butt AA, Yan P, Bonilla H, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology 2015; 62: 365–74.
24. Butt AA, Yan P, Lo Re VIII, et al. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175:178–85.
25. Butt AA, Khan UA, Shaikh OS, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009; 10: 25–32.
26. World Health Organization. Haemoglobin Concentrations for the Diagnosis of Anaemia and Assessment of Severity. Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011 WHO/NMH/NHD/MNM/11 1. Available at http://www.who.int/vmnis/indicators/haemoglobin.pdf. Accessed: 04 March 2016.